Spring til...

  • Hovedindhold
  • Indholdsfortegnelse
  • Sidefod
  • Dansk da
    • Publications
    • People
      • Staff
      • Experts
    • Topics
    • About VIVE
    • Contact
    • Dansk
    • Dansk
    • English
Other 1. AUG 2023

Does a mandatory switch from originator adalimumab to biosimilar GP2017 or SB5 lead to increased hospital costs? A DANBIO study of >1,300 patients with inflammatory arthritis

Authors:

  • N. Nabi
  • Rikke Ibsen
  • M. Ibsen
  • Jakob Kjellberg
  • M. Hetland
  • B. Glintborg
Page created Monday, February 26, 2024 Page updated Tuesday, September 24, 2024

Authors

  • N. NabiRikke IbsenM. IbsenJakob KjellbergM. HetlandB. Glintborg

About this publication

  • Published in

    Scandinavian journal of rheumatology
VIVE – The Danish Center for Social Science Research provides knowledge that contributes to developing the welfare society and strengthening quality development, efficiency enhancement and governance in the public sector, both in municipalities, regions and nationally.
Tel: +45 44 45 55 00
E-mail: vive@vive.dk
EAN: 5798000354845
CVR: 23 15 51 17